Researchers from the National Research Centre of Egypt and Cairo University have reported the discovery of novel acetylcholinesterase (AChE) inhibitors as candidates for the management of Alzheimer’s disease.

Triple-negative breast cancer (TNBC) is a highly metastatic and heterogeneous type of tumor, representing 15% of breast cancer cases. To tackle the drug-resistant phenotype of TNBC, effective targeted combinatorial approaches are urgently needed. Writing in EMBO Molecular Medicine journal, researchers from the Centre for Genomic Regulation and collaborators demonstrate that the simultaneous inhibition of lysyl oxidase-like 2 (LOXL2) and bromodomain-containing protein 4 (BRD4) synergistically limits TNBC proliferation in vitro and in vivo.

Treatment of osteoarthritis (OA) is still a challenge, since it is focused on symptom relief but fails at dealing with the progressive cartilage deterioration that occurs during the disease. Researchers from Innovo Therapeutics Inc. recently unveiled INV-1498, a caspase inhibitor, as a preclinical candidate for the treatment of OA.

Scientists from the University of Cambridge, Harvard Medical School and collaborators investigated the potential of ubiquitin carboxyl-terminal hydrolase 30 (USP30) inhibition as a therapeutic strategy for restoring mitophagy to achieve neuroprotection in Parkinson’s disease.

Neumora Therapeutics Inc. has announced IND clearance and initiation of a phase I study of NMRA-266 in healthy adults.